BioSpace News Archive

POXEL SA (Euronext: POXEL - FR0012432516), today announced its results for the year ended December 31, 2021 and provided a corporate update.

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced it received US Food and Drug Administration (FDA) clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular occlusion.

Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced financial results for the three months and year ended December 31, 2021 and provided a corporate update.

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced that management will participate in one-on-one investor meetings and a fireside chat at the Stifel 2022 CNS Days conference.

Synthetic Biologics, Inc. announced that Company’s Management will provide a corporate update and participate in a panel discussion entitled “Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim 2022 Virtual Growth Conference, to be held virtually March 28-March 30, 2022.

Longboard Pharmaceuticals, Inc. announced that Kevin Lind, Longboard’s President & Chief Executive Officer, will present at the Maxim Group LLC Virtual Growth Conference, taking place March 28–30, 2022.

The FDA and representatives from the medical device industry have reached an agreement on proposed recommendations for the fifth reauthorization of the medical device user fee program.

Avinger, Inc., a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, reported results for the fourth quarter and full year ended December 31, 2021.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Adial’s Chief Executive Officer will participate in a fireside chat at the 2022 Virtual Growth Conference.

Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), announced today that Dr. Daniel Alkon, the Company’s President and Chief Scientific Officer, will present a “Spotlight Showcase” of Synaptogenix under the title “Regenerative Therapeutics” on Tuesday, March 22nd at 8am ET.